Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Aldosterone as a determinant of cardiovascular and renal dysfunction.

× No keyword cloud information.

43 in total

Review 1. Aldosterone and vascular damage.

Authors: D Duprez; M De Buyzere; E R Rietzschel; D L Clement
Journal: Curr Hypertens Rep Date: 2000-06 Impact factor: 5.369

2. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production.

Authors: N J Brown; K S Kim; Y Q Chen; L S Blevins; J H Nadeau; S G Meranze; D E Vaughan
Journal: J Clin Endocrinol Metab Date: 2000-01 Impact factor: 5.958

3. Aldosterone activates Na+/H+ exchange in vascular smooth muscle cells by nongenomic and genomic mechanisms.

Authors: S Ebata; S Muto; K Okada; J Nemoto; M Amemiya; T Saito; Y Asano
Journal: Kidney Int Date: 1999-10 Impact factor: 10.612

Review 4. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift.

Authors: M Epstein
Journal: J Hypertens Date: 2001-05 Impact factor: 4.844

5. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.

Authors: N J Brown; S Nakamura; L Ma; I Nakamura; E Donnert; M Freeman; D E Vaughan; A B Fogo
Journal: Kidney Int Date: 2000-09 Impact factor: 10.612

6. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.

Authors: C A Farquharson; A D Struthers
Journal: Circulation Date: 2000-02-15 Impact factor: 29.690

7. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.

Authors: B Pitt; G Williams; W Remme; F Martinez; J Lopez-Sendon; F Zannad; J Neaton; B Roniker; S Hurley; D Burns; R Bittman; J Kleiman
Journal: Cardiovasc Drugs Ther Date: 2001-01 Impact factor: 3.727

8. Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats.

Authors: Y Sun; J Zhang; J Q Zhang; F J Ramires
Journal: Hypertension Date: 2000-05 Impact factor: 10.190

9. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors: B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal: N Engl J Med Date: 1999-09-02 Impact factor: 91.245

10. Cardiovascular complications in patients with primary aldosteronism.

Authors: M Nishimura; T Uzu; T Fujii; S Kuroda; S Nakamura; T Inenaga; G Kimura
Journal: Am J Kidney Dis Date: 1999-02 Impact factor: 8.860

11 in total

Review 1. Mineralocorticoid receptors in vascular function and disease.

Authors: Amy McCurley; Iris Z Jaffe
Journal: Mol Cell Endocrinol Date: 2011-06-24 Impact factor: 4.102

2. Aldosterone stimulates surface expression of NHE3 in renal proximal brush borders.

Authors: Alexander W Krug; Friderun Papavassiliou; Ulrich Hopfer; Karl J Ullrich; Michael Gekle
Journal: Pflugers Arch Date: 2003-04-09 Impact factor: 3.657

3. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.

Authors: K J Schjoedt; S Andersen; P Rossing; L Tarnow; H-H Parving
Journal: Diabetologia Date: 2004-11-17 Impact factor: 10.122

Review 4. Aldosterone: a risk factor for vascular disease.

Authors: Mario Fritsch Neves; Ernesto L Schiffrin
Journal: Curr Hypertens Rep Date: 2003-02 Impact factor: 5.369

5. Aldosterone-receptor antagonism and end-stage renal disease.

Authors: Niall McLaughlin; Todd W B Gehr; Domenic A Sica
Journal: Curr Hypertens Rep Date: 2004-08 Impact factor: 5.369

Review 6. Application of direct renin inhibition to chronic kidney disease.

Authors: Christian W Mende
Journal: Cardiovasc Drugs Ther Date: 2010-04 Impact factor: 3.727

7. An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice.

Authors: Guangyu Zhou; Ulrika Johansson; Xiao-Rong Peng; Krister Bamberg; Yufeng Huang
Journal: Am J Transl Res Date: 2016-03-15 Impact factor: 4.060

8. Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial.

Authors: Morten Lindhardt; Frederik Persson; Gemma Currie; Claudia Pontillo; Joachim Beige; Christian Delles; Heiko von der Leyen; Harald Mischak; Gerjan Navis; Marina Noutsou; Alberto Ortiz; Piero Luigi Ruggenenti; Ivan Rychlik; Goce Spasovski; Peter Rossing
Journal: BMJ Open Date: 2016-03-02 Impact factor: 2.692

9. Examination of the association of steroids with fluid accumulation in critically ill patients, considering the possibility of biases.

Authors: Amit Frenkel; Ran Abuhasira; Yoav Bichovsky; Anton Bukhin; Victor Novack; Evgeni Brotfain; Alexander Zlotnik; Moti Klein
Journal: Sci Rep Date: 2021-03-10 Impact factor: 4.379

10. Arterial plasma vasopressin and aldosterone predict left ventricular mass in men who develop hypertension over 20 years.

Authors: Arne H Strand; Helga Gudmundsdottir; Eigil Fossum; Ingrid Os; Reidar Bjørnerheim; Sverre E Kjeldsen
Journal: J Clin Hypertens (Greenwich) Date: 2007-05 Impact factor: 3.738